-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Cognition Therapeutics Study Of Zervimesine (CT1812) In Early Alzheimer’s Disease Surpasses 50% Enrollment Target

Reuters·07/01/2025 11:32:58

Please log in to view news